MedTrace Logo

CyberKnife Dose Escalation Prostate Cancer Trial

NCT03822494 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-02-21

No results posted yet for this study

Summary

Stereotactic body radiation therapy (SBRT) has been employed in the treatment of prostate cancer. Multiple single institution experiences suggest high biochemical control rates with acceptable toxicity in low risk prostate cancer but efficacy data in unfavorable type prostate cancer is less convincing. CyberKnife-SBRT (CK-SBRT) can be used to escalate radiation dose delivery to the prostate while sparing normal tissue.

Conditions

Interventions

RADIATION

CyberKnife SBRT

Radiation Therapy

Sponsors & Collaborators

  • Crozer-Keystone Health System

    lead OTHER

Principal Investigators

  • Rachelle Lanciano, MD · Philadelphia CyberKnife -Crozer Health

  • Rachelle Lanciano, MD · Philadelphia CyberKnife -Crozer Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-12
Primary Completion
2023-06-21
Completion
2028-07-12
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03822494 on ClinicalTrials.gov